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SUMMARY
Loss of the JunB/AP-1 transcription factor induces amyeloproliferative disease (MPD) arising from the hema-
topoietic stem cell (HSC) compartment. Here, we show that junB inactivation deregulates the cell-cycle
machinery and increases the proliferation of long-term repopulating HSCs (LT-HSCs) without impairing their
self-renewal or regenerative potential in vivo. We found that JunB loss destabilizes a complex network of
genes and pathways that normally limit myeloid differentiation, leading to impaired responsiveness to
both Notch and TGF-b signaling due in part to transcriptional deregulation of the Hes1 gene. These results
demonstrate that LT-HSC proliferation and differentiation are uncoupled from self-renewal and establish
some of the mechanisms by which JunB normally limits the production of myeloid progenitors, hence pre-
venting initiation of myeloid malignancies.INTRODUCTION
The mammalian hematopoietic system provides a unique, trac-
table model for investigating how cancer-associated mutations
affect the behavior of specific cell populations and lead to the
development of blood cancer or leukemia (Orkin and Zon,
2008). Hematopoietic development is organized hierarchically,
starting with a rare population of hematopoietic stem cells
(HSCs) that gives rise to a series of committed progenitors and
mature cells with particular functional and immunophenotypic
properties. HSCs are operationally defined by their ability to
provide long-term multilineage reconstitution when transplanted
into hematopoietically compromised recipients and are the only
cells that self-renew throughout life. HSCs are found predomi-nantly in the bone marrow (BM) associated with several recently
described vascular and endosteal niches (Kiel and Morrison,
2008). A complex balance of cell-intrinsic regulators and cell-
extrinsic factors present in these niches normally maintain
HSCs in a state of relative dormancy and regulate their trafficking
to and from these BM niches. Under steady-state conditions,
HSCs are a largely quiescent, slowly cycling cell population
that, in response to environmental stresses, is capable of
dramatic expansion and contraction to ensure proper homeo-
static replacement of blood cells (Passegue´ et al., 2005).
Gene knockout studies in mice have demonstrated that regu-
lation of HSC numbers can be accomplished through direct
modulation of HSC proliferative activity, resistance to apoptosis,
and retention in the BM niches (Orkin and Zon, 2008). ImportantSIGNIFICANCE
Understanding how clonal dominance occurs in the hematopoietic stem cell (HSC) compartment is a central issue in leuke-
mogenesis. Here, we show that inactivation of the JunB transcription factor causes cell-cycle deregulation, disrupts the
complex transcriptional network controlling proliferation and differentiation, and decreases responsiveness to Notch and
TGF-b signaling. This renders the HSC compartment insensitive to the limits on expansion and myeloid differentiation
imposed by those signals. Together, these deregulations lead to the aberrant expansion of myeloid progenitors andmyelo-
proliferative disease development in vivo without causing long-term repopulating HSC (LT-HSC) exhaustion. Our results
provide a mechanism explaining how mutations that increase the proliferation of a single LT-HSC can become dominant
and lead to the expansion of an aberrant clone within the otherwise normal HSC compartment.Cancer Cell 15, 341–352, April 7, 2009 ª2009 Elsevier Inc. 341
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as the D cyclins and the cyclin-dependent kinase inhibitors
(CKIs) p21/CIP1 and p18/INK4c. Recent studies have also high-
lighted the roles of specific signal transducers (Pten), transcrip-
tion factors (Gfi1, HoxB4, HoxA9), and extrinsic regulatory path-
ways (Notch, TGF-b, Wnt) in controlling HSC self-renewal and
proliferation (Akala and Clarke, 2006; Blank et al., 2008).
However, the precise molecular circuitry controlling HSC fate
decisions has yet to be fully elucidated, and the mechanisms
by which HSC maintenance, proliferation, and differentiation
are coordinately regulated to ensure homeostatic production of
blood cells remain poorly understood. Recently, it has been sug-
gested that changes in the quiescence status of HSCs (Holyoake
et al., 1999) and deregulation of their interaction with BM niches
(Jin et al., 2006) could be key events for their leukemic transfor-
mation and the development of myeloid leukemia. Still, little is
known about the impact of leukemic transformation on HSC bio-
logical function and how abnormal HSC-derived leukemia-initi-
ating stem cells (LSCs) differ from normal HSCs.
Originally discovered in leukemia, cancer-initiating stem cells
have now been recognized in a variety of solid tumors (Wang
and Dick, 2005). They represent a subset of a heterogeneous
cancer population and are operationally defined by their ability
to drive the formation and growth of a new tumor in transplanted
mice. Convincing evidence indicates that LSCs are inefficiently
eliminated by current therapeutic treatments and suggests that
LSC persistence could be responsible for disease maintenance
and/or recurrence (Jordan et al., 2006). Developing therapeutic
interventions that specifically target LSCs, an appealing strategy
for improving leukemia treatment, requires an understanding of
how LSCs escape normal regulatory mechanisms and become
malignant. Few mouse models of human leukemia are currently
available in which the LSC population has been identified and
can be purified for analysis (Wang and Dick, 2005). This is an
essential prerequisite for identifying pathways and molecules
available for interventional therapies in patients.
We have previously developed several mouse strains lacking
the JunB/AP-1 transcription factor that accurately recapitulate
important clinical aspects of human myeloid malignancies,
including chronic myelogenous leukemia (CML) (Passegue´
et al., 2001). We have also identified the LSC population as
arising from the HSC compartment during the precancerous
myeloproliferative disease (MPD) phase (Passegue´ et al.,
2004). Importantly, junB inactivation has been observed in
a spectrum of human myeloid malignancies, including CML
(Yang et al., 2003), and downregulation of junB expression has
been found in the HSC compartment of patients with acute
myeloid leukemia (Steidl et al., 2006). At present, little is known
about the role of JunB in HSC biology and myeloid leukemia
development. Here, we used junB-deficient mice as a model
system to understand how JunB normally controls HSC func-
tions and to identify the deregulated mechanisms that are
responsible for HSC transformation into LSCs.
RESULTS
Defects in Hematopoietic Reconstitution
To evaluate the impact of junB loss on HSC function in hemato-
poietic reconstitution, we first performed competitive BM trans-342 Cancer Cell 15, 341–352, April 7, 2009 ª2009 Elsevier Inc.plantation experiments (Figure 1A). Control and junB-deficient
BM cells (1 3 106 total) were mixed in a 1:1 or 9:1 ratio with
GFP-expressing competitor BM cells and injected into lethally
irradiated recipients. Regardless of the donor/competitor ratio
used, we found that junB-deficient BM cells consistently dis-
played 50% reduced engraftment efficiency compared to
control BM cells. We then directly transplanted 1 3 106 control
or junB-deficient BM cells into lethally or sublethally irradiated
recipients (Figure 1B and data not shown). While transplantation
into lethally irradiated mice yielded comparable reconstitution
levels (Passegue´ et al., 2004), transplantation into sublethally
irradiated mice revealed extremely variable engraftment levels,
with junB-deficient BM cells being on average 50% less efficient
than control BM cells. To confirm the limited engraftment of
junB-deficient cells, we transplanted small numbers of an
HSC-enriched population (defined as Flk2/Lin/Sca-1+/c-Kit+
or Flk2 LSK BM cells, hereafter referred to as hematopoietic
stem and progenitor cells [HSPCs]) together with 33 105 unfrac-
tionated helper BM cells into lethally irradiated recipients
(Figure 1C; see also Table S1 available online). While no engraft-
ment was observed after injection of 50 to 100 junB-deficient
HSPCs, transplantation of 250 junB-deficient HSPCs resulted
in a 2- to 10-fold decrease in reconstitution levels depending
mainly upon the use of Sca-1-depleted (HSC-purged) helper
BM cells. In every case in which junB-deficient HSPCs engrafted
(even at low levels), we observed progressive expansion of the
myeloid lineage, leading by 6 to 12 months posttransplantation
to the development of an MPD (Figure 1D) similar to the disease
observed in primary junB-deficient mice (Passegue´ et al., 2004).
The engraftment process requires that transplanted HSCs
home to the BM cavity and cross the endothelial layer forming
the wall of the blood vessels (Lapidot et al., 2005). To assess
whether junB-deficient HSPCs are defective in BM homing, we
performed short-term in vivo homing assays by injecting lethally
irradiated recipients with GFP+ Flk2 LSK cells or LSK cells iso-
lated from junB-deficient mice crossed to b-actin GFP trans-
genic mice. Analysis of peripheral blood (PB), BM, spleen, and
the hematopoietic component of the liver for the presence of
GFP+ cells at 3 or 12 hr postinjection revealed similar numbers
of control and junB-deficient HSPCs in all tissues, including
BM, at both time points (Figure 1E and data not shown). We
also used intrafemoral injections of 1 3 106 BM cells into suble-
thally irradiated recipients to confirm that impaired homing did
not contribute to the reduced engraftment of junB-deficient cells
(Figure 1F; Figure S1). Taken together, these results indicate that
despite normal lodging in the BM cavity after transplantation,
junB-deficient HSPCs are impaired in their ability to engraft in
the BM niches and to contribute to hematopoietic reconstitution.
This suggests either that junB-deficient HSCs are defective in
BM maintenance or that fewer long-term repopulating
HSCs (LT-HSCs) are present in the transplanted junB-deficient
populations.
Deregulated Cell-Cycle Distribution
HSC engraftment following transplantation as well as mainte-
nance during steady-state hematopoiesis critically depends
upon their quiescent state (Passegue´ et al., 2005). We next
investigated whether the engraftment defects observed with
junB-deficient HSPCs could result from changes in their
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Figure 1. Hematopoietic Reconstitution Potential and
Homing Activity of junB-Deficient Bone Marrow Cells
Lethally or sublethally irradiated recipients (CD45.1) were
transplanted with the indicated number and type of donor
control or junB-deficient cells (CD45.2). Mice were bled every
4 weeks and analyzed for % CD45.2 chimerism in the periph-
eral blood (PB).
(A) Transplantation of 1 3 106 unfractionated bone marrow
(BM) cells (1:1 and 9:1 ratio of donor and competitor GFP+/
CD45.1 cells) into lethally irradiated recipients (n = 5 mice per
cohort). Engraftment efficiency factor (percentages ± SD)
was calculated as ([%CD45.2+ donor cells]/[(%CD45.1+ recip-
ient and competitor cells) 3 (% GFP+ competitor cells)]).
(B) Transplantation of 1 3 106 unfractionated BM cells into
sublethally irradiated recipients (n = 5 mice per cohort).
(C) Transplantation of 250 purified hematopoietic stem and
progenitor cells (HSPCs: Flk2 LSK) together with 3 3 105
helper CD45.1 BM cells into lethally irradiated recipients (n =
4 mice per cohort).
(D) Myeloproliferative disease (MPD) development in recipients
of junB-deficient BM cells (red dots in [B]). The % CD45.2
chimerism and donor-derived myeloid (Gr-1+/Mac-1+) cells in
PB and the total cell numbers for the indicated BM subpopula-
tions are given at 6 months posttransplantation (averages ±
SD; n = 3mice per cohort; **p% 0.01, ***p% 0.001). MPP,mul-
tipotent progenitors (Flk2+ LSK); MP, myeloid progenitors
(Lin/Sca-1/c-Kit+); CMP, common myeloid progenitors;
GMP, granulocyte/macrophage progenitors; MEP, megakar-
yocyte/erythrocyte progenitors.
(E) Short-term in vivo homing assay. Sublethally irradiated
recipients (n = 3 mice per cohort) were injected with either
50,000 LSK cells (3 hr) or 10,000 Flk2 LSK cells (12 hr) isolated
from b-actin GFP control and junB-deficient mice. The number
(averages ± SD) of transplanted GFP+ cells present in the BM
was determined at 3 or 12 hr postinjection.
(F) Intrafemoral injections. 1 3 106 unfractionated BM cells
were injected directly into the femoral cavity of sublethally irra-
diated recipients (one femur injected per mouse, n = 3–4 mice
per cohort).cell-cycle distribution. Analyses performed using either live
Hoechst 33342 (H)/pyronin Y (PY) staining on purified Flk2
LSK cells or intracellular 7-aminoactinomycin D (7AAD)/PY stain-
ing on unfractionated BM cells (Figure 2A; Table S2) revealed
that junB-deficient HSPCs had on average a 2-fold decrease in
the percentage of quiescent G0 cells and a correlative increase
in the percentage of cycling G1 and S-G2/M cells. Short-term
kinetic analysis of bromodeoxyuridine (BrdU) incorporation indi-
cated increased proliferation rates in junB-deficient HSPCs, with
13% of BrdU+ cells after 1 hr incorporation reaching 24% after
12 hr compared to 8% and 19%, respectively, for control
HSPCs (Figure 2B and data not shown). Ki-67 and phosphohi-
stone H3 immunofluorescence staining on isolated Flk2 LSK
cells further confirmed that junB-deficient HSPCs have a higher
proliferative index (Table S2).
To understand the deregulations occurring at the molecular
level, we used quantitative RT-PCR (qRT-PCR) to analyze the
expression level of a comprehensive panel of cell-cycle genes
in Flk2 LSK cells isolated from pools of control mice (3–5
mice) or from age-matched individual junB-deficient mice
(Figure 2C). Although significant fluctuations in gene expressionwere observed between the individual junB-deficient HSPC pop-
ulations (likely reflecting differences in the stage of MPD devel-
opment in the respective donor mice), we found a consistent
decrease in the expression levels of early G1 cyclins (mainly
D1) and of two CKIs (p18 and p57), associated with a trend
toward increased expression of late G1 cyclins (E1 and E2) and
S-G2/M cyclins (A2 and F). Furthermore, we confirmed a
decrease in cyclin D1 protein levels in junB-deficient HSPCs
using intracellular fluorescence-activated cell sorting (FACS)
analysis (Figure 2D). Taken together, these results provide
a molecular signature of the deregulations occurring in the cell-
cycle regulation of junB-deficient HSPCs and a mechanism for
their enhanced proliferation.
Quiescence Status and Engraftment Potential
Increased proliferation and altered ratios of quiescent versus
cycling HSPCs may indicate that the engraftment defect
observed with junB-deficient cells results from transplanting
fewer numbers of quiescent HSCs. To test this hypothesis,
Flk2 LSK cells were isolated, stained with H/PY, and re-sorted
for the G0 subset, after which 250 G0 HSPCs were transplantedCancer Cell 15, 341–352, April 7, 2009 ª2009 Elsevier Inc. 343
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dose of Sca-1-depleted helper BM cells (Figure 3A). Surprisingly,
we found that junB-deficient G0 HSPCs still displayed severe
defects in hematopoietic reconstitution compared to the same
number of control G0 HSPCs. This result prompted our reevalua-
tion of the cell surface marker combination used to identify
engrafting HSCs by performing intracellular 7AAD/PY staining
for cell-cycle distribution together with additional molecules
that enrich for LT-HSC activity: CD34 (Osawa et al., 1996) and
the signaling lymphocyte attractant molecule (SLAM) markers
CD150 and CD48 (Kiel et al., 2005). As expected, using the
CD34 marker we identified a highly quiescent CD34/Flk2 LSK
population in control mice (Figure S2). However, in the junB-defi-
cient mice, the CD34/Flk2 LSK cells also displayed aberrant
cell-cycle distributionwithmassive recruitment intoG1 andsignif-
icant expansion in numbers. In sharp contrast, using the SLAM
markers, we identified a highly quiescent CD150+/CD48/Flk2
LSK population (G0, 92.4% ± 3.5% versus 89.5% ± 3.8%; G1-
S-G2/M, 2.2% ± 2.3% versus 10.5% ± 4.1%; n = 5) that was of
similar size in both control and junB-deficient mice (Figures 3B
and 3C). This staining strategy also revealed that the increase in
sizeof the junB-deficientHSPCcompartmentwascausedalmost
entirely by an increase in CD48+/Flk2 LSK cells (Figure 3B).
Subsequently, we transplanted 250 CD150+/CD48/Flk2
LSK or CD48+/Flk2 LSK cells into lethally irradiated recipients
A B
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Figure 2. Deregulated Proliferation and Regulation of
the Cell-Cycle Machinery in junB-Deficient HSPCs
(A) Live Hoechst (H)/pyronin Y(PY) staining of purified control
and junB-deficient HSPCs. Quiescent G0 cells are H
2n/PY
while proliferative G1 and S-G2/M cells are H
2n/PY+ and
HR2n–4n/PY+, respectively. Bottom histograms indicate DNA
content.
(B) BrdU incorporation (1 hr in vivo pulse) in purified control and
junB-deficient HSPCs. Cells in S phase (boxed) are BrdU+ and
haveR2n DNA content as determined by propidium iodide (PI)
counterstaining (bottom histograms).
(C) Quantitative RT-PCR analysis of cell-cycle gene expression
in control and junB-deficient HSPCs. Flk2 LSK cells were iso-
lated from pools of 3–5 control mice and from age-matched
individual junB-deficient mice. The results shown are averages
of triplicate measurements and are expressed as log2(fold
difference) compared to the levels found in control HSPCs
(*p % 0.05, **p % 0.01, ***p % 0.001; b-actin normalization).
For each gene, 3–9 independent samples were analyzed per
genotype (some red dashes are overlapping).
(D) Intracellular fluorescence-activated cell sorting (FACS)
analysis of cyclin D1 protein levels in control and junB-deficient
HSPCs and myeloid progenitors (MP: Lin/Sca-1/c-Kit+).
to investigate their engraftment potential
(Figure 3D). As expected, neither control nor junB-
deficient CD48+/Flk2 LSK cells provided long-
term reconstitution (Kiel et al., 2005). In fact,
CD48+/Flk2 LSK cells only gave rise to a transient
myeloid readout without long-lasting lymphoid cell
production (data not shown), and their progenies
were almost completely absent from the recipient
mice at 1 month posttransplantation (Figure 3D).
Strikingly, junB-deficient CD150+/CD48/Flk2
LSK cells displayed quantitatively enhanced and more robust
repopulating activity than control cells, which reflects their
increased production of mature myeloid cells. By 11 months
posttransplantation, robust and sustained engraftment was
observed in both cohorts (control, 78% ± 14% chimerism;
junB-deficient, 93% ± 2% chimerism; n = 5), accompanied by
MPD development in mice transplanted with junB-deficient cells
(data not shown). Taken together, these results demonstrate that
CD150+/CD48/Flk2 LSK cells are the true quiescent and
engrafting LT-HSCs in both control and junB-deficient mice.
They also indicate that the reconstitution defects observed
upon transplantation of junB-deficient unfractionated BM or
purified HSPCs result from dilution of these engrafting LT-HSCs
by the expanded, nonengrafting CD48+/Flk2 LSK cells. Further-
more, they provide an explanation for the puzzling outcome of
the G0 HSPC transplantation experiments (Figure 3A) since the
transplanted junB-deficient G0 HSPCs contained a much larger
fraction of nonengrafting G0 CD48
+/Flk2 LSK cells (Figure S3)
than control G0 HSPCs, hence again diluting the true engrafting
quiescent LT-HSCs.
Increased Proliferation with Normal
Regenerative Potential
Next, we tested whether junB-deficient LT-HSCs, despite main-
taining normal numbers in the BM, could have increased344 Cancer Cell 15, 341–352, April 7, 2009 ª2009 Elsevier Inc.
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described recently (Kiel et al., 2007) (Figure 4A; Table S3).
Control and junB-deficient mice were injected intraperitoneally
with BrdU (1 mg/6 g body weight) and then fed BrdU (1 mg/ml)
in their drinking water for up to 10 days. LT-HSCs (CD150+/
CD48/Flk2 LSK cells) were isolated, and the cells that incorpo-
rated BrdU while replicating their DNA were enumerated by
immunofluorescence analysis. In addition, we also quantified
BrdU incorporation by intracellular FACS analysis (Figure S4).
Using both detection methods, we found that junB-deficient
LT-HSCs displayed significantly increased BrdU incorporation
compared to control LT-HSCs, reaching 60.7% ± 2.5% versus
42.5% ± 0.7% (n = 4; p% 0.005) after 10 days of BrdU adminis-
tration. Cell-cycle entry rates, calculated by regression on the log
of the proportion of unlabelled cells (Cheshier et al., 1999),
revealed that 13.6% of junB-deficient LT-HSCs entered the
cell cycle each day (with a population doubling time of 16.3
days), compared to only 6.4% per day for control LT-HSCs
(with a population doubling time of 26.9 days). We also per-
formed qRT-PCR analysis for the expression of quiescence-
and cell-cycle-associated genes in junB-deficient LT-HSCs
A
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Figure 3. Persistence of a Highly Quiescent Long-
Term Repopulating Hematopoietic Stem Cell Popula-
tion with Normal Engraftment Potential in junB-Defi-
cient Mice
(A) Hematopoietic reconstitution from quiescent HSPCs. Flk2
LSK cells were isolated from control and junB-deficient mice
(CD45.2), stained with H/PY, and re-sorted for the G0 (H
2n/
PY) subpopulation. Lethally irradiated recipient mice
(CD45.1; n = 3 per cohort) were injected with 250 purified G0
HSPCs together with 3 3 105 Sca-1-depleted helper CD45.1
BM cells and analyzed monthly for percentages (±SD) of
CD45.2 chimerism in PB (***p% 0.001).
(B) SLAM marker subfractionation of the HSPC compartment
in control and junB-deficient mice. The FACS plots show
examples of CD150 and CD48 expression in the Flk2 LSK
compartment, and the bottom graph summarizes the total
numbers (averages ± SD) of Flk2 LSK and SLAM subsets in
control (n = 7) and junB-deficient (n = 5) mice (**p% 0.01).
(C) Cell-cycle analysis of CD150+/CD48/Flk2 LSK cells in
control and junB-deficient mice. BM cells were stained for
CD150 expression in the Flk2 LSK compartment (with
CD48 included in the lineage cocktail; see Figure S3) in combi-
nation with intracellular staining for cell-cycle distribution
(7-aminoactinomycin D [7AAD]/PY). Quiescent G0 cells are
7AAD2n/PY while proliferative G1 and S-G2/M cells are
7AAD2n/PY+ and 7AADR2n–4n/PY+, respectively.
(D) Hematopoietic reconstitution from CD150+/CD48/Flk2
LSK and CD48+/Flk2 LSK subsets. Cells were isolated from
CD45.2 control and junB-deficient mice, and 250 cells for
each subset were injected together with 3 3 105 Sca-1-
depleted helper CD45.1 BM cells into lethally irradiated
CD45.1 recipients. Mice (n = 5 per cohort) were analyzed every
4 weeks for % (±SD) CD45.2 chimerism in PB (*p % 0.05,
**p% 0.01, ***p% 0.001).
(Figure 4B). Interestingly, we found a significant
increase in the expression level of G0/G1 transition
kinase cyclin C together with changes already
observed in junB-deficient HSPCs, mainly
decreased expression of the CKIs p18, p57, and cyclin D1 and
increased expression of the mitotic cyclin A2.
The increased proliferation of junB-deficient LT-HSCs raised
the possibility that these cells might exhaust faster than normal
LT-HSCs under regenerative stress conditions, as suggested
by other studies using transplantation of more or less purified
cell populations (Orford and Scadden, 2008). To address this
question without using the transplantation system, we evaluated
hematopoietic recovery and survival after serial injections of the
myelosuppressive agent 5-fluorouracil (5-FU; 150 mg/kg)
(Figure 4C). When 5-FU was injected every second month (to
allow complete recovery between injections), both control and
junB-deficient mice started dying by the third 5-FU injection
without any significant difference between the two groups. As
expected, junB-deficient mice always displayed higher restora-
tion levels of the myeloid lineage than control mice, indicating
constant regeneration of the MPD from junB-deficient LT-HSCs
that persisted after 5-FU treatment. When 5-FU was injected
every 7 days (to continuously deplete regenerating progenitor
populations), both control and junB-deficient mice also
displayed similar survival rates, with the majority of deathsCancer Cell 15, 341–352, April 7, 2009 ª2009 Elsevier Inc. 345
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cate that junB-deficient LT-HSCs have regenerative potential
similar to, and do not exhaust faster than, control LT-HSCs.
Taken together with the transplantation data, these data demon-
strate that the fast-cycling junB-deficient LT-HSCs have normal
self-renewal activity in vivo.
Broad Transcriptional Deregulations
To determine how loss of JunB affects HSC fate decisions, we
first analyzed junB-deficient HSPCs by qRT-PCR for the expres-
sion levels of genes known to play a role in self-renewal, quies-
cence, proliferation regulation, and oncogenic transformation
(Figure 5A). Overall, we found a general trend toward decreased
gene expression in junB-deficient Flk2 LSK cells, with signifi-
cant reductions in the levels of Pten, Hoxb4, and Hoxa9 (self-
renewal genes) and Notch1, Hes1, and Hes5 (Notch pathway
genes); nonsignificant reductions in N-myc and c-Myb (onco-
genes); and no changes in cell-cycle regulators and TGF-b
pathway components. To exclude measuring changes reflecting
only the expansion of the CD48+/Flk2 LSK cells observed in
junB-deficient mice, we also analyzed the expression of the
self-renewal genes in LT-HSCs (Figure 5B). While Pten, Hoxb4,
Hoxa9, and Notch1 did not exhibit significant changes in quies-
cent junB-deficient LT-HSCs, the expression of Hes1 (a key
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Figure 4. Deregulated Turnover Rates but Normal
Regeneration Potential in junB-Deficient Long-Term
Repopulating Hematopoietic Stem Cells
(A) Long-term kinetics of BrdU incorporation in long-term
repopulating hematopoietic stem cells (LT-HSCs). CD150+/
CD48/Flk2 LSK cells were isolated from individual control
and junB-deficient mice fed with BrdU for the indicated
number of days (n = 2–3 mice per time point). Images show
representative examples of BrdU staining (scale bar =
100 mm; arrowheads indicate BrdU+ LT-HSCs). BrdU
enumeration upon immunofluorescence detection (upper
right; averages ± SD) and calculation of the regression on
the log of the proportion of unlabeled cells (bottom) are also
shown.
(B) Quantitative RT-PCR analysis of cell-cycle gene expres-
sion in control and junB-deficient LT-HSCs. CD150+/CD48/
Flk2 LSK cells were isolated from pools of age-matched
control and junB-deficient mice (2–3 mice per pool, n = 3).
Results shown are averages of triplicate measurements and
are expressed as log2(fold difference) compared to the levels
found in control LT-HSCs (*p% 0.05; b-actin normalization).
(C) Serial 5-fluorouracil (5-FU) injections. Control and
junB-deficient mice were injected intraperitoneally with
150 mg/kg 5-FU (asterisks) either every 2 months or every
7 days. For the 2-month protocol (left), the kinetics of myeloid
recovery following 5-FU injection were evaluated. The results
(averages ± SD) show myeloid cell counts in PB as assessed
by automated complete blood count (CBC). For the 7-day
protocol (right), survival rates postinjection were determined.
downstream mediator of both Notch and TGF-b
pathways) (Blokzijl et al., 2003) remained signifi-
cantly decreased. Furthermore, preliminary chro-
matin immunoprecipitation (ChIP) analysis in wild-
type HSPCs and detailed promoter studies in 3T3
fibroblasts identified two repeated JunB binding
sites in the proximal region of the mouse Hes1 promoter and
demonstrated that JunB was a direct transcriptional activator
of Hes1 expression (Figure S5).
To functionally assess the status of the Notch pathway in
junB-deficient HSCs, we performed a short-term coculture
experiment on control OP9 stromal cells or OP9 stromal cells
expressing the Notch ligand Delta-1 (OP9DL1). Control and
junB-deficient HSPCs were sorted directly into a 96-well plate
containing either OP9 or OP9DL1 cells, grown for 48 hr with or
without g-secretase inhibitor (g-SI) to prevent activation of
the Notch pathway, and analyzed by qRT-PCR for Hes1 expres-
sion levels (Figure 5C). When cultured on OP9DL1 cells,
control HSPCs displayed a strong induction of Hes1 expression
that was completely abrogated upon g-SI treatment. In
contrast, Hes1 expression was not significantly induced in
junB-deficient HSPCs cultured on OP9DL1 cells, which demon-
strated a defective response to Notch stimulation in these cells.
We also confirmed defective induction of Hes1 expression in
junB-deficient LT-HSCs cocultured for 48 hr on OP9DL1 cells
(Figure 5C). To assess the status of the TGF-b pathway, we
incubated sorted control and junB-deficient HSPCs for 8 hr
with recombinant TGF-b and measured by qRT-PCR the
expression levels of three direct transcriptional targets of this
pathway: Smad7, the CKI p57, and Hes1 (Figure 5D). We found346 Cancer Cell 15, 341–352, April 7, 2009 ª2009 Elsevier Inc.
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Extracellular Signaling Pathway Genes in junB-Defi-
cient LT-HSCs
(A) Quantitative RT-PCR analysis of the expression levels of
genes and pathways controlling HSC fate decisions in control
and junB-deficient HSPCs. The same cDNA samples used in
Figure 2C were used for this analysis (*p % 0.05, **p % 0.01,
***p% 0.001).
(B) Quantitative RT-PCR analysis of control and junB-deficient
LT-HSCs. The same cDNA samples used in Figure 4B were
used for this analysis (*p% 0.05, **p% 0.01).
(C) Control or junB-deficient HSPCs or LT-HSCs (3,000 cells
per well) were directly sorted into 96-well plates containing
either OP9 (Notch) or OP9DL1 (Notch+) cells and incubated
for 48 hr with or without g-secretase inhibitor (g-SI; 10 mM).
The data shown for each population are the averages ± SD
of two independent experiments each performed in triplicate
(*p% 0.05, ***p% 0.001; b-actin normalization). HSPC results
are expressed as fold increase compared to Hes1 levels in
control or junB-deficient cells cocultured on OP9 cells without
g-SI (arbitrarily set to 1). LT-HSC results are expressed as fold
decrease compared to Hes1 levels in control cells cocultured
on OP9DL1 cells without g-SI (arbitrarily set to 1).
(D) Control or junB-deficient HSPCs (3,000–20,000 cells per
well) were directly sorted into 96-well plates, rested overnight,
and stimulated with 5 ng/ml TGF-b for 8 hr. The results are
expressed as fold increase compared to Smad7, p57, and
Hes1 levels found in nonstimulated HSPCs incubated for the
same length of time. Independent measurements (each per-
formed in triplicate) from 3–6 experiments and averages
(bars) are shown (*p% 0.05, **p% 0.01, ***p% 0.001; RL-19
normalization).significantly reduced induction of all three genes in junB-defi-
cient HSPCs compared to control HSPCs, indicating that these
cells are also defective in their response to TGF-b stimulation.
Taken together, these results indicate that loss of JunB desta-
bilizes a broad network of interconnected genes and pathways
that regulate HSC fate decisions and demonstrate that JunB is
essential to control the extent to which HSCs respond to Notch
and TGF-b stimulation, due in part to JunB involvement in the
transcriptional regulation of the common downstream effector
gene Hes1.
Increased Myeloid Differentiation in Response
to Impaired Notch and TGF-b Regulations
Finally, we asked whether the defective response of junB-defi-
cient HSCs to Notch and TGF-b stimulation could contribute to
the increased myelopoiesis observed in junB-deficient mice.
To answer this question, control and junB-deficient HSPCs
and LT-HSCs were first cocultured for 4 days on OP9 or
OP9DL1 cells in the presence or absence of TGF-b (Figure 6A).
This initial step was designed to assess growth in response to
activation of Notch and TGF-b pathways, similar to what is likely
provided by the BMniches in vivo. Control cells were also treated
with g-SI and TGF-b inhibitor (T-bI; 5 mM) to mimic the dual
impairment observed in junB-deficient HSPCs. After 4 days of
coculture, these HSPC- or LT-HSC-derived cells were trans-
ferred into methylcellulose containing a cocktail of myeloid cyto-
kines and growth factors (but devoid of TGF-b or inhibitors) to
assess myeloid colony-forming activity (CFU). This second
step allowed us to estimate the numbers of myeloid progenitorsgenerated in each coculture condition. As expected, stimulation
with TGF-b and activation of the Notch pathway (alone or in
combination) severely limited growth and myeloid differentiation
from control cells compared to untreated cultures (Figures 6B
and 6C). In contrast, similar treatments did not significantly
inhibit junB-deficient HSPC or LT-HSC expansion rates. Most
strikingly, neither Notch induction nor TGF-b stimulation was
able to limit myeloid differentiation from junB-deficient cells,
which matched the myeloid differentiation potential obtained in
untreated cultures (Figures 6B and 6C). Similarly, pharmacolog-
ical inhibition of Notch and TGF-b signaling in control HSPCs or
LT-HSCs partially prevented the growth inhibition and fully
relieved the block in myeloid differentiation imposed by these
regulatory mechanisms. Taken together, these results indicate
that Notch and TGF-b cooperate to limit the rate at which
LT-HSCs and early progenitor cells expand (via both pathways)
and differentiate (mostly via TGF-b) to produce myeloid progen-
itors. They also suggest that lack of response to Notch and TGF-
b contributes to the ability of junB-deficient LT-HSCs to constitu-
tively overproduce myeloid progenitors and to induce MPD
development in vivo.
DISCUSSION
In this study, we identified some of the mechanisms by which
JunB regulates LT-HSC functions and elucidated how inactiva-
tion of this key transcription factor can lead to overproduction
of myeloid progenitors and MPD development in vivo. We found
that JunB normally controls LT-HSC proliferation and limits theirCancer Cell 15, 341–352, April 7, 2009 ª2009 Elsevier Inc. 347
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B C Figure 6. Defective Notch and TGF-b Pathway
Responsiveness Contributes to the Overproduction
of Myeloid Progenitors from junB-Deficient LT-HSCs
(A) Schematic of the experimental design. Cells were directly
sorted into 96-well plates (1,000 cells per well) containing
OP9 (Notch) or OP9DL1 (Notch+) cells and incubated for
4 days with or without 5 ng/ml TGF-b in the presence or
absence of TGF-b inhibitor (T-bI; 5 mM) and g-secretase
inhibitor (g-SI; 10 mM). Cells where then counted and replated
in methylcellulose to determine the percentage of cells with
myeloid colony-forming activity (CFU) present in each culture
condition.
(B) Comparison between control and junB-deficient HSPCs.
The results shown are the averages ± SD of four independent
experiments performed in duplicate (**p% 0.01, ***p% 0.001).
(C) Comparison between control and junB-deficient LT-HSCs.
The results shown are the averages ± SD of two independent
experiments performed in triplicate (*p % 0.05, **p % 0.01,
***p% 0.001).rate of production of myeloid progenitors by maintaining appro-
priate responsiveness to Notch and TGF-b signaling, in part
through transcriptional regulation of Hes1, an important medi-
ator of both pathways. These functions place JunB at the center
of the complex network of cell-intrinsic and cell-extrinsic signals
that ensure coordinated regulation of LT-HSC proliferation and
differentiation, independently of LT-HSC maintenance and self-
renewal activity. Taken together, our results provide a potential
mechanism for disease initiation in the range of human myeloid
malignancies in which junB inactivation has already been
reported (Yang et al., 2003; Steidl et al., 2006). Moreover, they
expand our current understanding of the normal biology of the
HSC compartment and the abnormal properties of HSC-derived
LSCs.
Rethinking Transplantation AssaysUsed to Analyze HSC
Number and Activity
HSCs have been defined and studied for many decades based
on their ability to engraft and reconstitute the blood system of
transplanted mice (Orkin and Zon, 2008). This functional prop-
erty has allowed for the phenotypic identification and isolation
of progressively more enriched HSC populations (Table S4).
Hence, it has become common practice to enumerate HSCs
by performing limiting dilution transplantation experiments with
unfractionated BM cells. While this technique provides a valid
assessment of HSC numbers in normal situations, our results
demonstrate that it is a potentially unreliable method of deter-
mining HSC number and function in pathological situations.
Hence, when we compared the same numbers of control and
junB-deficient unfractionated BM cells or enriched but not pure
HSC populations (Flk2 LSK cells or HSPCs) side by side, we
observed engraftment defects from junB-deficient cells associ-
ated with deregulated cell-cycle distribution, loss of quiescence,
and impaired serial transplantability by the third passage (data
not shown). Only upon isolation of HSCs to near functional purity
(using CD150+/CD48/Flk2 LSK surface markers, one of the
best phenotypic combinations currently available) did we348 Cancer Cell 15, 341–352, April 7, 2009 ª2009 Elsevier Inc.uncover that junB-deficient LT-HSCs had in fact normal engraft-
ment capability as well as normal cell-cycle distribution, with
more than 90% of the BM population quiescent at any given
time. By using the same amount of unfractionated BMor partially
purified HSPCs for both genotypes, we mistakenly injected
fewer of the engrafting LT-HSCs and more of the overproduced
nonengrafting differentiating cells for junB-deficient populations
than for control populations (Table S4). This dilution effect was
also observed when we transplanted the quiescent fraction of
the junB-deficient HSPC compartment, as the expanded
CD48+/Flk2 LSK subset also displayed a large portion of quies-
cent cells (Figure S3). These results have at least two important
implications. First, they demonstrate that quiescence per se is
not a defining characteristic of LT-HSCs and should not be
used as the sole criterion for identifying this cell population,
even in an enriched subset. In fact, most of the early progenitor
cells, including short-term hematopoietic stem cells and multi-
potent progenitors, have R50% of their population in the G0
phase of the cell cycle at any given time (Passegue´ et al.,
2005). Second, our results indicate that one must transplant
a highly purified cell population when assessing LT-HSC
numbers and properties in situations in which artificially intro-
duced genetic alterations (in mice) or naturally occurring muta-
tions (in humans) can affect the biological activity of the HSC
compartment, leading to either overproduction or underproduc-
tion of differentiating cells. Incorrect assumptions may otherwise
be made regarding the number and self-renewal activity of these
mutant LT-HSCs.
Proliferation and HSC Maintenance
Several studies have suggested that increased HSC proliferation
may lead to stem cell exhaustion and loss of maintenance in the
BM microenvironment (Orford and Scadden, 2008). Here, we
show that junB-deficient LT-HSCs incorporate BrdU twice as
fast as normal LT-HSCs due to direct or indirect changes in
the regulation of their cell-cycle machinery (i.e., increases in
cyclin C and cyclin A2 expression and decreases in cyclin D1,
Cancer Cell
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BM numbers, quiescence status, engraftment, or regenerative
potential in vivo. These results clearly demonstrate that HSC
maintenance in the BM niches and self-renewal activity are not
solely dictated by LT-HSC proliferation rate. One question raised
by these observations is how nearly identical numbers of quies-
cent LT-HSCs can be maintained in the BMmicroenvironment in
both control and junB-deficient mice. One possibility is that
junB-deficient LT-HSCs could have shorter cell-cycle length,
leading to increased turnover rates and BrdU accumulation
without an increase in population size or decrease in G0
frequency. Another possibility is that junB-deficient LT-HSCs
have increased proliferation (without changes in the length of
their cell cycle) but that the overproduced LT-HSCs are dis-
placed from the BM (perhaps due to lack of available niches)
and released into the periphery, where they eventually become
exhausted. This would imply the existence of retention mecha-
nisms provided by the BM niches that would specifically main-
tain a preset number of quiescent LT-HSCs over an excess of
cycling LT-HSCs. While such mechanisms are still poorly under-
stood, they are likely to involve cell-cell and cell-matrix adhesion
molecules such as a4/b1-VLA4 integrins, CD44, or CXCR4/SDF-
1a, which are expressed on HSCs and are important for their
retention in the BM. Increased numbers of functional LT-HSCs
are found in the PB, liver, and spleen of junB-deficient mice
(unpublished data), which also develop pronounced extramedul-
lary hematopoiesis (Passegue´ et al., 2004), suggesting that
displacement of overproduced LT-HSCsmight indeed be occur-
ring in these mice as has already been found in other related
mutant mice (Min et al., 2008).
Control of HSC Differentiation
Despite being extensively studied, the intricate molecular
machinery and signaling mechanisms that coordinately regulate
HSC proliferation and differentiation have remained largely
elusive (Akala and Clarke, 2006; Blank et al., 2008). Here, we
showed that at least two developmentally conserved signaling
pathways that play a controversial role in HSC self-renewal
(Notch and TGF-b) are in fact critical for limiting the rate at which
HSCs produce myeloid progenitors. First, we found that the
MPD-producing junB-deficient LT-HSCs have impaired respon-
siveness to both Notch activation and TGF-b stimulation as
measured by decreased induction of downstream effectors of
these pathways (i.e., Smad7, p57, and Hes1). Second, using
normal LT-HSCs and pharmacological inhibitors, we showed
that impairing responsiveness to the TGF-b pathway in the pres-
ence of attenuated Notch stimulation leads to deregulated
production of myeloid progenitors in vitro. Notch signaling has
been shown to be necessary for maintaining HSCs in an undiffer-
entiated state in the presence of proliferative signals in vitro
(Duncan et al., 2005). Recently, it has been reported that the
complete absence of canonical Notch signaling does not affect
LT-HSC maintenance and self-renewal in vivo (Maillard et al.,
2008). TGF-b is one of the most potent inhibitors of HSC growth
in vitro (Sitnicka et al., 1996) and a negative regulator of myelo-
poiesis in vivo (Letterio and Roberts, 1998). Similar to Notch, it
has been shown that absence of TGF-b signaling does not affect
LT-HSC maintenance and self-renewal in vivo (Larsson et al.,
2005). Taken together with our findings, these observationssuggest that Notch and TGF-b belong to a complex network of
signaling mechanisms provided by the BM niches that limit the
rates at which LT-HSCs proliferate and producemyeloid progen-
itors without affecting their maintenance and self-renewal
activity (see model in Figure 7A). In this context, JunB appears
essential to maintain appropriate responsiveness to both Notch
and TGF-b signaling due to its direct or indirect function in main-
taining the expression levels of key downstream effectors of
these pathways, including the Hes1 gene. As a consequence,
loss of JunB renders the HSC compartment refractory to these
negative regulatory mechanisms, resulting in increased produc-
tion of myeloid progenitors and MPD development in vivo.
Deconstructing the JunB Transcriptional Network
in HSCs
Here, we have demonstrated that JunB is a core transcriptional
regulator of HSC functions that controls a vast network of inter-
connected genes and pathways involved in numerous fate deci-
sions including proliferation and earlymyeloid differentiation (see
model in Figure 7B). We also identify Hes1 as a direct JunB tran-
scriptional target that could be involved in mediating part of
these effects. However, direct or indirect deregulation of other
effector genes including (but not limited to) Hes5, Notch1,
Pten, HoxB4, and HoxA9 is likely to play a role in establishing
or maintaining the aberrant biological functions displayed by
junB-deficient HSPCs. Furthermore, it remains to be determined
how loss of JunB results in the activation of LT-HSC cell-cycle
machinery. JunB is a known transcriptional activator of p16 (Pas-
segue´ andWagner, 2000) and a transcriptional repressor of both
cyclin D1 and cyclin A (Bakiri et al., 2000; Andrecht et al., 2002).
While we did observe the expected increase in cyclin A2 in junB-
deficient HSPCs, neither p16 (unchanged) nor cyclin D1
(decreased) behaved as predicted. It is possible that still
uncharted changes in other transcriptional regulators and/or
signaling pathways could counterbalance the direct effect of
loss of JunB on the expression level of those genes. Alterna-
tively, differences in JunB-mediated transcriptional regulation
in distinct cell types (fibroblasts versus HSCs) or other confound-
ing factors, such as the age of the mice, could explain these
discrepancies. In fact, decreased p16 expression is observed
in junB-deficient HSPCs isolated from older MPD mice (Pas-
segue´ et al., 2004), consistent with an enhanced role for p16 in
controlling the biology of aging HSCs (Janzen et al., 2006).
Genome-wide ChIP analysis will be required to gain a better
understanding of these complex regulations and further delin-
eate the JunB transcription network in HSCs.
LSC Transformation
Our results indicate that deregulating the network of signaling
mechanisms that control the balance between HSC proliferation
and differentiation can lead to aberrant myeloid progenitor
expansion and MPD development without causing LT-HSC
exhaustion. These findings have important implications for
understanding the development of myeloid malignancies in
humans. They provide a mechanism to explain how mutations
that increase the proliferation of a single LT-HSC can become
dominant and lead to the expansion of an aberrant clone within
the otherwise normal HSC compartment. They also explain
how human LSCs emerging from the HSC compartment, suchCancer Cell 15, 341–352, April 7, 2009 ª2009 Elsevier Inc. 349
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A Figure 7. JunB Is a Key Transcriptional Regulator of
the HSC Compartment that Controls LT-HSC Prolifer-
ation and Differentiation without Affecting Self-
Renewal
(A) Model summarizing the defective regulation of junB-defi-
cient LT-HSCs. Normal LT-HSCs (left) in their BM microenvi-
ronment are maintained as slowly cycling, mostly quiescent
cells due to the concerted action of a complex network of
extrinsic regulatory pathways that provide multiple stop
signals to limit proliferation and rates of myeloid progenitor
production. In the absence of junB expression (right),
LT-HSCs lose responsiveness to at least two of these key
negative regulatory pathways (Notch and TGF-b), leading to
a dampening of the stop signals provided by the BMmicroen-
vironment. As a result, junB-deficient LT-HSCs display
increased turnover rates without overt expansion in the BM
niches (most likely due to increased migration into the
periphery) and overproduce myeloid progenitors, leading to
MPD development in vivo. Importantly, junB-deficient
LT-HSCs have normal self-renewal potential, indicating that
the mechanisms controlling LT-HSC maintenance are unaf-
fected in these leukemia-initiating stem cells (LSCs).
(B) The JunB transcriptional network in hematopoietic stem
and early progenitor cells. Lines (arrow = activation; blunted =
inhibition) represent confirmed (solid) or unconfirmed (dotted)
direct JunB transcriptional targets.as in CML, can be maintained as a quiescent, self-renewing,
nonexpanding population that overproduces myeloid progeni-
tors and mature cells (Holyoake et al., 1999) and resists most
current antileukemia treatments (Jordan et al., 2006). Similar to
junB-deficient LT-HSCs escaping 5-FU killing and regenerating
the MPD in treated mice, CML LSCs might escape therapeutic
treatment by taking advantage of the intact HSC-associated
protection mechanisms provided by the BM niches. It is also
tempting to speculate that BCR-ABL (the fusion oncoprotein
encoded by the t(9;22) translocation, the hallmark of CML) might
act very similarly to junB inactivation by deregulating differentia-
tion without affecting LT-HSC self-renewal mechanisms. It will
be interesting to use the spectrum of deregulation observed in
junB-deficient HSCs as a road map to investigate BCR-ABL-
expressing HSCs and determine whether similar pathways are
affected. This type of comparison could uncover common de-
regulated mechanisms used by different oncogenic events and
identify shared targets available for therapeutic intervention
aimed at limiting LSCs’ aberrant functional properties or prevent-
ing HSC transformation into LSCs.
EXPERIMENTAL PROCEDURES
Mice
Congenic C57BL/6-CD45.1 mice were used as donors (4–6 weeks old) for
purification of wild-type cells and as recipients (8–12 weeks old) for transplan-
tation experiments. Control and junB-deficient (junBfl/flMORE-Cre) C57BL/6-
CD45.2 mice have been described previously (Passegue´ et al., 2004).
b-actin-GFP C57BL/6-CD45.1 transgenic mice (Forsberg et al., 2006) were
used as donors (4–6 weeks old) for purification of GFP-expressing competitor
cells and to obtain, upon crossing, GFP-expressing control and junB-deficient350 Cancer Cell 15, 341–352, April 7, 2009 ª2009 Elsevier Inc.mice. 5-FU (150 mg/kg) was administrated by intraperitoneal injection. All
animal experiments were performed in accordance with protocols approved
by the University of California, San Francisco Institutional Animal Care and
Use Committee.
Flow Cytometry
Cell preparation, staining, analysis, and isolation procedures were performed
as described previously (Forsberg et al., 2006; Kiel et al., 2005). Additional
information can be found in Table S5. After staining, cells were resuspended
in Hank’s buffered saline solution (HBSS) containing 2% heat-inactivated
FBS (HyClone) and 1 mg/ml propidium iodide for dead cell exclusion and
were sorted on a FACSAria or analyzed on a LSR II (Becton Dickinson).
Each subpopulation was double sorted and reanalyzed to ensure maximum
purity.
Transplantations
Congenic recipient mice were irradiated using a cesium source irradiator with
lethal (1200 rad) or sublethal (950 rad) doses delivered in a split dose 3 hr apart
and were given antibiotic-containing water for at least 6 weeks postirradiation.
For in vivo homing experiments, mice were irradiated 1 day prior to injections.
For all other transplantation experiments, mice were injected immediately after
irradiation. For intravenous injections, cells were resuspended in a volume of
100 ml and injected into the retro-orbital plexus. For intrafemoral injections,
cells were resuspended in a volume of 30 ml and injected through the knee
into the femoral cavity of anesthetized mice. Donor and recipient cells were
distinguished by expression of GFP or different allelic forms of CD45
(CD45.1 versus CD45.2).
Cell Cycle and Intracellular Staining
Short- and long-termBrdU kinetics as well as live Hoechst 33342 (H)/pyronin Y
(PY) staining were performed as described previously (Passegue´ et al., 2005;
Kiel et al., 2007) (Table S5). Intracellular 7-aminoactinomycin D (7AAD)/PY and
cyclin D1 staining of unfractionated BM cells were performed as described in
Table S5.
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Total RNA was isolated using TRIzol reagent (Invitrogen), digested with DNase
I, and used for reverse transcription according to the manufacturer’s instruc-
tions (SuperScript III kit, Invitrogen). qRT-PCR primers were designed using
Primer Express software (Applied Biosystems) (Table S6). All reactions were
performed in an ABI 7300 sequence detection system using SYBR Green
PCR Core reagents (Applied Biosystems) and cDNA equivalent of 200 cells
per reaction as described previously (Forsberg et al., 2006). Expression levels
of b-actin or ribosomal protein L-19 (RL-19) genes were used to normalize the
amount of the investigated transcripts.
Cell Cultures
Hematopoietic cocultures were performed in Iscove’s modified Dulbecco’s
medium (IMDM) containing 5% FBS, 13 penicillin/streptomycin, 2 mM Gluta-
Max-1, 0.1 mM nonessential amino acids, 1 mM sodium pyruvate, and 50 mM
2-mercaptoethanol and supplemented with 25 ng/ml of SCF, Flt3-L, and IL11.
For coculture experiments, HSCs were sorted directly over a monolayer of
OP9 and OP9DL1 cells plated in a 96-well plate (5,000–20,000 cells per well)
and grown for up to 4 days (with medium addition every 2 days) with or without
5 ng/ml recombinant human TGF-b1 (R&D Systems), 10 mM g-secretase inhib-
itor (XXI; Calbiochem), and/or 5 mM TGF-b inhibitor (SB431542; Sigma).
Following the culture period, HSC-derived cells were collected, transferred
in a 96-well plate, incubated for 20 min at 37C to deplete for contaminating
stromal cells, re-collected, rinsed once with HBSS, and then either resus-
pended in TRIzol reagent for RNA isolation or counted, diluted (1:3 to 1:50),
and replated in methylcellulose. Myeloid colony-forming activity was evalu-
ated after 4 days of culture in IMDM-based methylcellulose medium (M3231;
Stem Cell Technologies) supplemented with SCF (25 ng/ml), Flt3-L (25 ng/ml),
IL-11 (25 ng/ml), IL-3 (10 ng/ml), Tpo (25 ng/ml), Epo (4 U/ml), and GM-CSF
(10 ng/ml).
Statistical Analysis
p values were calculated using Student’s unpaired t test.
SUPPLEMENTAL DATA
The Supplemental Data include Supplemental Experimental Procedures,
Supplemental References, six tables, and five figures and can be found with
this article online at http://www.cancercell.org/supplemental/S1535-6108
(09)00072-5.
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